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The most common form of hereditary retinal blindness 
is retinitis pigmentosa (RP), which affects about 1 in 4,000 
people worldwide. The disease typically begins with patients 
experiencing night blindness, due to the early involvement 
of rod photoreceptors, and progresses with a decrease in the 
visual field and loss of central vision, due to the degeneration 
of cone photoreceptors [1]. Patients affected with RP display 
clinical heterogeneity regarding age of onset, degree of 
severity, rate of progression, and other secondary manifesta-
tions. These differences are partly explained by the different 
genes and mutations that cause RP. To date, more than 60 
genes have been associated with non-syndromic RP, with 
about 3,000 mutations reported in total; however, a substan-
tial fraction of cases are negative for mutations in known 
disease genes [2]. The inheritance mode is classically mono-
genic: dominant (about 30–40%), recessive (about 50–60%), 
X-linked (5–15%), and a smaller fraction of non-Mendelian 
or complex inheritance [1].
The functions of RP genes can be diverse: some genes 
are specific for retinal function such as phototransduction and 
retinal metabolism, while others have a more general func-
tion in cell development and maintenance [3]. A particular 
category that exemplifies the complexity of the molecular 
genetics of RP is represented by a few highly conserved and 
ubiquitously expressed pre-mRNA splicing factors.
Splicing consists of consecutive reactions occurring in 
the nucleus and leading to the removal of introns from pre-
mRNA to form mature mRNA. A macromolecular complex, 
referred to as the spliceosome, ensures the fidelity and the 
correct timing of these reactions. The core components of 
the spliceosome are five small nuclear ribonucleoproteins 
(snRNP), U1, U2, U4, U5, and U6 [4], that assemble on the 
pre-mRNA in an ordered, stepwise manner. U1 snRNP first 
recognizes the 5′ splice site, and U2 binds to the branch point; 
then the U4/U6.U5 tri-snRNP complex is recruited, and 
finally U1 and U4 are released, leading to catalytic activa-
tion [5].
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Purpose: Mutations in genes encoding proteins from the tri-snRNP complex of the spliceosome account for more than 
12% of cases of autosomal dominant retinitis pigmentosa (adRP). Although the exact mechanism by which splicing fac-
tor defects trigger photoreceptor death is not completely clear, their role in retinitis pigmentosa has been demonstrated 
by several genetic and functional studies. To test for possible novel associations between splicing factors and adRP, 
we screened four tri-snRNP splicing factor genes (EFTUD2, PRPF4, NHP2L1, and AAR2) as candidate disease genes.
Methods: We screened up to 303 patients with adRP from Europe and North America who did not carry known RP 
mutations. Exon-PCR and Sanger methods were used to sequence the NHP2L1 and AAR2 genes, while the sequences 
of EFTUD2 and PRPF4 were obtained by using long-range PCRs spanning coding and non-coding regions followed by 
next-generation sequencing.
Results: We detected novel missense changes in individual patients in the sequence of the genes PRPF4 and EFTUD2, 
but the role of these changes in relationship to disease could not be verified. In one other patient we identified a novel 
nucleotide substitution in the 5′ untranslated region (UTR) of NHP2L1, which did not segregate with the disease in the 
family.
Conclusions: The absence of clearly pathogenic mutations in the candidate genes screened in our cohort suggests that 
EFTUD2, PRPF4, NHP2L1, and AAR2 are either not involved in adRP or are associated with the disease in rare instances, 
at least as observed in this study in patients of European and North American origin.
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To date, six splicing factors genes have been found to 
be mutated in patients with adRP: PRPF8 (RP13; ID: 10594, 
OMIM 607300) [6], PRPF31 (RP11; ID: 26121, OMIM 
606419) [7], PRPF3 (RP18; ID: 9129, OMIM 607301) [8], 
PAP-1 (RP9; ID: 6100, OMIM 607331) [9], SNRNP200 
(RP33; ID: 23020, OMIM 601664) [10,11], and PRPF6 (ID: 
24148, OMIM 613979) [12]. The prevalence of mutations in 
adRP cases is estimated to be about 8% for PRPF31, 2–3% 
for PRPF8, 1–4% for PRPF3, 1.6% for SNRNP200, and to be 
rare for PAP-1 and PRPF6 [1,13,14], globally accounting for 
more than 12% of all adRP cases.
All these genes have a high level of protein sequence 
conservation up to yeast and belong to the U4/U6.U5 tri-
snRNP complex. The growing evidence of a major role of 
these particular splicing factors suggested that other partners 
of the complex could be meaningful candidate genes for 
adRP. Indeed, these mutations have been discovered through 
linkage analysis and positional cloning for the first two genes 
discovered (PRPF8 and PRPF31), followed by the sequencing 
of other splicing factor genes in linkage intervals or in large 
cohorts of patients. This latter strategy, commonly referred 
to as the candidate gene approach [15], has been (and still 
is) instrumental for discovering several new RP genes. For 
instance, the role of the PRPF6 gene in adRP was found with 
this approach, via the sequencing of the coding sequence in 
a cohort of 200 American patients [12].
Following the same rationale, we screened four candidate 
genes from the tri-snRNP complex in up to 303 patients with 
adRP with unknown molecular diagnosis and previously 
found to be negative for mutations in the most common adRP 
genes or hotspots. We selected the genes EFTUD2 (ID: 9343, 
OMIM 603892), PRPF4 (ID: 9128, OMIM 607795), NHP2L1 
(ID: 4809, OMIM 601304) and AAR2 (ID: 25980), because of 
their physical or functional interaction with known RP-linked 
splicing factors. In particular, EFTUD2 encodes for an essen-
tial GTPase, hSnu114, homolog of Saccharomyces cerevisiae 
Snu114p, which forms a stable complex with the SNRNP200 
and PRPF8 products (i.e., hBrr2 and PRPF8, both involved in 
adRP) [16]. hSnu114 regulates hBrr2 at the dissociation step 
of U4 from U6 and is necessary for spliceosome disassembly 
after splicing [17]. The AAR2 gene encodes Aar2p, which 
competes with hBrr2 in the binding of the C-terminal region 
of PRPF8 before the maturation of the U5 snRNP, supposedly 
regulating its assembly [18]. The 15.5-kDa protein (Snu13p 
in yeast), encoded by the NHP2L1 gene, binds to the 5′-stem-
loop of U4 snRNA probably playing a role in the late phase 
of the spliceosome assembly [19]. Finally, the PRPF4 protein 
forms a complex with PRPF3 in the U4/U6 snRNP complex, 
and its downregulation was found to induce photoreceptor 
defects in a zebrafish model, similarly to PRPF31 [20,21].
For the genetic screening we took advantage of a method 
that combines classical exon-PCR for the small genes and 
long-range PCR followed by next-generation sequencing for 
the large genes. The latter approach provides a cost- and time-
effective alternative to the Sanger method and adapts well to 
routine genetic screenings in large sets of samples.
METHODS
Samples and patients: The subjects analyzed in this cohort 
belong to three groups of unrelated patients affected with 
autosomal dominant retinitis pigmentosa. One hundred and 
ninety-one samples were collected at the Berman-Gund 
Laboratory, Harvard Medical School, Massachusetts Eye 
and Ear and are mostly of North American origin. They were 
previously screened and found to be negative for exonic muta-
tions by Sanger sequencing in 90% of all known adRP genes. 
One hundred and fifteen were collected in Spain (Servicio de 
Genética, IIS Fundación Jiménez Díaz University Hospital, 
Madrid) and were negative to a genotyping microarray that 
assessed known RP mutations [22]. Ninety-six were from 
France (INSERM U1051, Institut des Neurosciences de Mont-
pellier, Hôpital Saint Eloi, Montpellier) and before this study 
were sequenced and found to be negative for the ten most 
frequently mutated genes or hotspots (RHO (ID: 6010, OMIM 
180380), RDS (ID: 5961, OMIM 179605), PRPF31 (ID: 26121, 
OMIM 606419), RP1 (ID: 6101, OMIM 603937), PRPF8 (ID: 
10594, OMIM 607300), IMPDH1 (ID: 3614, OMIM 146690), 
NRL (ID: 4901, OMIM 162080), PRPF3 (ID: 9129, OMIM 
607301), NR2E3 (ID: 10002, OMIM 604485), and SNRNP200 
(ID: 23020, OMIM 601664) [23]. DNA was extracted from 
peripheral leukocytes and quantified. For technical reasons, 
only a subset of these samples could undergo the complete 
screening of the four genes but all (402 individuals) were 
analyzed for putative mutations in specific exons. Control 
DNA samples were obtained from 95 individuals with no 
history of retinal degeneration and 96 unrelated healthy 
individuals between age 34 and 92, purchased from the 
Coriell Institute for Medical Research. All subjects provided 
written, informed consent, and the study was conducted in 
adherence with the Declaration of Helsinki. This research 
was approved by the Institutional Review Boards of our 
respective Universities or Hospitals: University of Lausanne, 
Fundación Jiménez Díaz University Hospital, Institut des 
Neurosciences de Montpellier, Harvard Medical School, and 
the Massachusetts Eye and Ear.
Library preparation and next-generation sequencing: Genes 
EFTUD2 and PRPF4 were sequenced with long-range PCR 
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(LR-PCR) followed by next-generation sequencing (NGS), 
using Illumina instruments (San Diego, CA). Five and two 
LR-PCRs were generated to amplify the entire 51- and 20-kb 
regions of each gene, respectively, for a total of 71-kb targeted 
region. LR-PCRs were obtained individually for each sample 
using TaKaRa LA Taq polymerase (Takara Bio, Shiga, Japan) 
with GC buffer and 1 µM of the primers reported in Appendix 
1.The following cycling conditions were used: 94 °C for 1 min 
followed by 30 cycles at 98 °C for 5 s and 68 °C for 15 min, 
and final extension of 72 °C for 10 min. For each sample, the 
seven LR-PCRs were pooled into a single tube, after their 
quantity was estimated on agarose 1% gel. They were subse-
quently purified using DNA Clean and Concentrator columns 
(Zymo Research, Orange, CA). Only the DNA samples from 
the three cohorts that yielded seven clear PCR bands under-
went NGS, resulting in 200 samples in total.
Library preparation and sample barcoding were 
performed as described by Adey et al. [24] using the Nextera 
DNA Sample Prep Kit (Epicenter, Madison, WI) and 48 
barcodes adapted to Illumina platforms [25], following the 
manufacturer’s instructions. Fourteen tagged samples were 
sequenced as a pool in one lane of the GAII instrument for 
testing purposes, after which two runs of the HiSeq instru-
ment (one lane for each run) were used to sequence two pools 
of 48 and 47 barcoded samples each. After the Nextera prod-
ucts were integrated by Illumina, we processed 91 additional 
samples using the Nextera XT DNA Sample Preparation 
(Illumina) protocol, reagents, and barcodes, and sequenced 
the samples as a unique pool with one Miseq instrument run.
Analysis and variant calling of sequences from next-genera-
tion sequencing: We mapped the reads obtained from NGS to 
the reference sequence of the genes (GRCh37.p10 assembly) 
with the CLC Genomics Workbench package, v. 5.5 (CLC bio, 
Aarhus, Denmark). The parameters were in a way that a read 
could align only if it had at least a 90% identity for the 90% 
of its length. A more relaxed setting (80% identity over 70% 
of its length) was also tried. Single nucleotide variant calling 
and small insertion and deletion calling were achieved by 
imposing a minimum frequency of discordant bases of 20%, 
with minimum coverage of five nucleotides and an average 
base quality of 20 Phred. The analyses were performed as a 
batch of all individual samples (200), and the obtained vari-
ants were annotated with the hg19_snp137 track from the 
UCSC Genome Browser.
Analysis of variant identified: To exclude polymorphisms, 
we consulted the databases dbSNP, 1000 Genomes, Exome 
Variant Server, Complete Genomics’ 42 control individuals, 
and exome sequencing data from 500 individuals from the 
CoLaus cohort [26]. Missense changes were analyzed with 
the online package PON-P, which integrates the results of 
the most common prediction software, including PolyPhen 
and SIFT [27]. The effect of intronic changes was evaluated 
with the Shannon Human Splicing Pipeline, kindly offered 
to us as a free trial by Cytognomix (London, Canada) and 
implemented in the CLC software [28], and the NNSPLICE 
0.9 algorithm [29].
Sanger sequencing and restriction analysis: The genes 
NHP2L1 and AAR2 were screened with Sanger sequencing 
of the coding exons. PCR reactions were obtained with 
the GoTaq polymerase (Promega, Madison, WI) standard 
protocol and 0.25 µM of the primers reported in Appendix 
2. Reactions were purified from excess primers and nucleo-
tides with ExoSAP-IT (Affymetrics, Santa Clara, CA) and 
subjected to sequencing reactions using the Big Dye V1.1 
Terminator Kit (Applied Biosystems, Foster City, CA) 
and an ABI automated DNA sequencer (Applied Biosys-
tems). Sequences were analyzed using the CLC Genomics 
Workbench (CLC bio). The same procedure was applied to 
validate the novel changes in specific exons identified with 
NGS, cosegregation analysis, and screening of controls and 
additional patients. Primers used for these purposes are listed 
in Appendix 2. In some instances, controls and additional 
patients were tested using restriction enzymes when a partic-
ular nucleotide change abolished or created a restriction site. 
In particular, exon 5 of PRPF4 was tested with MscI, exon 
8 of EFTUD2 with HahI, and exon 1 of NHP2L1 with MluI 
(New England Biolabs, Ipswich, MA).
RESULTS
Screening of PRPF4 and EFTUD2: We obtained LR-PCR 
products spanning the genes PRPF4 and EFTUD2 for a 
total of 200 unrelated individuals diagnosed with adRP 
(Table 1). Seventy-nine patients were from North America, 
71 from France, and 50 from Spain. Following multiplexed 
runs of NGS instruments, we analyzed the sequencing 
reads by alignment to the reference genomic sequences of 
the targeted genes. Since different instruments were used, 
different samples had different coverage depths. Specifically, 
the samples sequenced with HiSeq had higher coverage than 
the ones sequenced with MiSeq, due to the lower throughput 
and higher number of samples sequenced with the latter 
(Appendix 3). With the exception of a few samples, the 
targeted region was optimally covered for reliable variant 
calling. This consisted in the detection of single nucleotide 
variations and small insertions and deletions by the CLC 
Genomics algorithm. After merging the results obtained 
individually for each sample, we obtained a total figure of 
1,195 variants identified, 591 of which are annotated variants 
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present at different frequencies in the analyzed cohort. By 
restricting the analysis to exonic changes, we identified in 
total six missense variants, of which one was later found to 
be a false positive due to low coverage, as ascertained with 
Sanger sequencing (not shown). The remaining five variants 
are listed in Table 2.
Within the PRPF4 sequence, we identified two annotated 
variants, p.His78Arg and p.Pro187Ala (Table 2). The first one 
corresponded to dbSNP entry rs1138958 and was present in 
60 European heterozygotes from the Exome Variant Server 
database; therefore, we considered the variant to be non-
pathogenic. The second variant, found in a single individual 
(ID: 001–417), involved nucleotide c.559C (NM_004697.3, 
exon 5), which was flagged in dbSNP as entry rs187531407 
and referred to a CCC>TCC (p.Pro187Ser) change, found 
only in two non-validated 1000 Genomes reports. We ascer-
tained that one of these reports (a low-coverage genome in 
an African sample) was a false positive, following validation 
with direct Sanger sequencing on the original DNA sample 
(ID: NA18933, Coriell DNA repository). Moreover, although 
the nucleotide is the same, the base change in the patient in our 
cohort was different compared to rs187531407. More specifi-
cally, we identified a CCC>GCC change, which resulted 
in p.Pro187Ala. Proline 187 is not fully conserved across 
different species and, according to predictions with different 
tools, the likelihood of pathogenicity of p.Pro187Ala is 
uncertain (Table 3). We followed up this change by analyzing 
controls and available relatives. Public databases, as well as 
sequencing of in-house controls, did not reveal the presence 
of this change. We then screened an additional 202 patients 
with adRP from the same cohorts for this specific variant, 
but this change was not found in any additional individuals. 
The affected sibling (ID: 226–1953) of the index patient also 
carried the same change, but other family members were 
not available for further segregation analysis. Since the base 
change is located within exon 5, at a 5-bp distance from the 
donor splice site, we also checked if splicing of this exon was 
affected. Bioinformatic prediction was negative, and reverse-
transcription (RT)–PCR of patient’s cDNA did not reveal 
missplicing events. In the absence of additional elements, we 
could neither exclude nor validate this change as a potential 
mutation.
Table 1. Genes analyzed in This sTudy and meThods.
Symbol Protein snRNP complex # exons Screening method # screened patients
EFTUD2 Elongation factor Tu GTP binding domain containing 2- 116 kDa U5 [13] 28 Nextera-NGS 200
PRPF4 PRP4 pre-mRNA processing factor 4 homolog – 60 kDa U4/U6 [17] 14 Nextera-NGS 200
NHP2L1 NHP2 non-histone chromosome protein 2-like 1- 15.5 kDa U4/U6.U5 [16] 4 Sanger 303
AAR2 AAR2 splicing factor homolog U5 [15] 4 Sanger 187
Table 2. VarianT ouTpuT from nGs screeninG of PRPF4 and EFTUD2 afTer filTerinG for codinG chanGes.
Gene Sample count Genomic Position Coding region change Amino acid change DATABASE
PRPF4 3/200 9:116049532 NM_004697.4:c.233A>G NP_004688.2:p.His78Arg rs1138958
PRPF4 1/200 9:116053770 NM_004697.4:c.559C>G NP_004688.2:p.Pro187Ala rs187531407
EFTUD2 1/200 17:42953357 NM_004247.3:c.814A>G NP_004238.3:p.Thr272Ala rs150633454
EFTUD2 1/200 17:42956968 NM_004247.3:c.658C>T NP_004238.3:p.Arg220Cys -
EFTUD2 1/200 17:42963986 NM_004247.3:c.238A>C NP_004238.3:p.
Ile80Leu
-
Genomic coordinates refer to assembly GRCh37.p10. Numbering of coding region starts at A of the ATG. Human variation database 
search included dbSNP 137, 1000 Genomes Project, Exome Variant Server, Complete Genomics control samples and 500 exomes from 
the CoLaus cohort.
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Of the three missense changes found in the EFTUD2 
gene two were novel and present in single individuals 
(p.Arg220Cys and p.Ile80Leu) while one (p.Thr272Ala) was 
a rare variant found in two heterozygote control African 
samples from Exome Variant Server (rs150633454; Table 
2). The p.Arg220Cys change (ID: 001–492) was confirmed 
with Sanger sequencing and predicted to be damaging by 
several prediction tools (Table 3). The residue is in fact 
highly conserved, from human to yeast. The change was not 
found in public variation databases, in 150 in-house controls 
tested, and in the remaining patients from the other cohorts 
consisting of the 202 patients with adRP. Although we veri-
fied that the patient’s healthy sister (ID: 226–2008) and son 
(ID: 226–2009) did not carry this change, the unavailability 
of other family members prevented us from investigating this 
variant further. The novel p.Ile80Leu missense and the rare 
p.Thr272Ala were predicted to be neutral, based on conserva-
tion and strength of change, and considered non-pathogenic. 
Moreover, for the p.Thr272Ala change it was possible to 
perform cosegregation analysis, and the results were negative.
Since with LR-PCRs we amplified coding and non-
coding regions of the target genes, we tested whether any 
novel variant identified could affect sequences important 
for splicing signals, including those located in deep intronic 
regions. We analyzed 1,008 variants in exons and introns of 
the EFTUD2 and PRPF4 genes with the Shannon Human 
Splicing Pipeline [28]. Only single nucleotide substitutions, 
but not insertions or deletions, could be tested with this 
method. No change inactivated or reduced the strength of 
the natural splice sites. Four hundred and thirty-four variants 
were predicted to alter the sequence information of cryptic 
splice sites. By filtering for variations that were not polymor-
phic and that resulted in the creation of a donor or acceptor 
splice site with greater strength than the natural splice site, 
only five variants remained (Appendix 4). Two were likely 
false positives because they were present only in one read out 
of fivefold coverage. For the remaining three, other predic-
tions were made using the NNSPLICE algorithm and did not 
agree with the one of the Shannon pipeline. According to 
NNSPLICE, in fact, in two cases the new cryptic splice sites 
were still weaker than the natural ones, and in one case the 
already existing cryptic site was weakened by the change. We 
therefore concluded that there were insufficient elements to 
study these variants further.
Finally, a second run of variant calling was performed 
on alignments obtained with less stringent criteria, to exclude 
the possibility of false negatives due to too rigid mapping 
parameters. This analysis increased by two times the number 
of known SNPs identified (999 versus 476) and by three times 
the number of non-reported changes (3,752 versus 1,195), indi-
cating a gain in sensitivity but also a decrease in specificity 
(Appendix 5). In fact, when we analyzed only the coding 
changes, in addition to the variants found with previous 
mappings, we obtained eight false positives, all found in the 
same sample and localized in a stretch of wrongly aligned 
reads, as became clear from inspection of the mapping.
Screening of NHP2L1 and AAR2: Two additional genes, 
NHP2L1 and AAR2, were also selected. Because of their rela-
tively small size, they were screened by Sanger sequencing 
(Table 1). NHP2L1 consists of two coding exons and two 
alternative 5′ untranslated regions (UTRs) containing the 
start codon. Sequencing of the four exons in 303 patients (182 
from the United States, 90 from France, and 31 from Spain) 
revealed only one novel change introducing an ATG start 
codon in the 5′ UTR, which was found in one patient (ID: 
001–245) and not in the control population. This change was 
potentially interesting because it creates an upstream open 
Table 3. characTerizaTion of noVel chanGes idenTified in The compleTe screeninG.
Patient’s origin Gene Change Polyphen prediction PON-P prediction Controls Segregation
German PRPF4 p.Pro187Ala Probably damaging
Unclassified, Prob-
ability of pathoge-
nicity: 0.27
0/189 Positive
American Indian- 
French Canadian/
Irish
EFTUD2 p.Arg220Cys Probably damaging
Pathogenic, Prob-
ability of pathoge-
nicity: 0.91
0/150 Positive
- EFTUD2 p.Ile80Leu Benign Neutral, Probability of pathogenicity: 0.02 Not available Not available
Italian NHP2L1 chr22:42078408 NM_005008.2:c.-46G>A Creation of upstream out of frame ORF 0/150 Negative
Prediction of pathogenicity was made using Polyphen and PON-P [22]. In addition to database consultation, in-house controls were per-
formed by direct Sanger sequencing (PRPF4) or restriction enzymes (EFTUD2 and NHP2L1).
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reading frame (uORF), the effect of which could be to reduce 
the rate of translation from the downstream, canonical ATG 
[30]. However, this change did not segregate with RP in the 
family.
The sequence of the AA2R gene was negative for novel 
variations in the American cohort (187 samples analyzed). 
Notably, we found a patient (ID: 001–156) with a frameshift 
change reported in the Exome Variant Server (NM_015511.3: 
c.351_352insC). The inspection of DNA variations in AA2R 
in the general population revealed the presence of several 
truncating variants, which indicates that this gene tolerates 
haploinsufficiency and that therefore its role is molecular 
pathology of adRP is unlikely.
DISCUSSION
The adRP-linked splicing factors PRPF31, PRPF3, PRPF8, 
PRPF6, and hBrr2 are all components of the U4/U6.U5 tri-
snRNP, suggesting that there is a common mechanism of 
pathogenesis in RP related to dysfunction of this complex. 
It has been shown that mutations in genes encoding these 
proteins impair the assembly of the tri-snRNP complex 
[31,32] or affect catalytic activation of the spliceosome [33], 
leading to pre-mRNA splicing defects and eventually to cell 
death [34-36]. Because of their higher requirement of RNA 
processing, photoreceptor cells are particularly sensitive 
to the accumulation of splicing defects, compared to other 
tissues or organs [36]. Mutations are thought to act through 
a haploinsufficiency mechanism because many determine 
either truncation and degradation of the protein and the 
transcript [37] or their instability and accumulation in Cajal 
bodies [34-36].
In this work, we wanted to investigate the hypothesis 
that interacting proteins of the same functional complex 
could also have a role in adRP, by screening their DNA 
sequences in well-characterized cohorts of dominant patients 
previously analyzed for the most prevalent RP genes. We 
selected components of the tri-snRNP complex that, based 
on functional studies, were found to regulate or interact with 
splicing factors that were already associated with adRP. We 
used an NGS-based approach that allowed a fast and parallel 
analysis of these few candidate genes in a large set of patients, 
enabling in principle the identification of very rare mutations, 
which are expected in the case of this disease. In recent years, 
the strategies aiming at identifying the molecular causes 
of Mendelian diseases, including RP, have shifted toward 
genome-wide sequencing of patients followed by unbiased 
or gene-driven prioritization of mutations. However, these 
approaches are more powerful when analyzing reces-
sive conditions or dominant diseases with no genetic 
heterogeneity. For a dominant disease with considerable 
genetic heterogeneity the computational analysis and valida-
tion elements necessary to find a significant association with 
heterozygous changes become more important [38]. There-
fore, we reasoned that for autosomal dominant RP screening 
many samples for candidate genes could still be an effective 
option. For our study, next-generation sequencing has been a 
practical tool for performing targeted resequencing quickly 
and comprehensively, even when applied to a hypothesis-
driven strategy such as the candidate gene approach.
Nevertheless, the sequencing of the coding exons of 
the genes NHP2L1 and AAR2 and of exons and introns of 
EFTUD2 and PRPF4 revealed a few variants that could have 
an effect at the protein level and that were absent from the 
general population. Only the p.Arg220Cys missense in the 
EFTUD2 gene was predicted to be damaging by multiple 
predictive tools; however, its putative pathogenicity could not 
be demonstrated in our patient with RP. Moreover, during the 
course of this screening the same gene was linked by exome 
sequencing to a class of rare and sporadic congenital malfor-
mation syndromes, in particular to mandibulofacial dysos-
tosis with microcephaly (OMIM 610536) [39,40]. In these 
patients the mutations were de novo heterozygous missense, 
frameshift, and null alleles. Although certain phenotypic 
variability was observed for the EFTUD2 mutations [41], it 
seems that they affect early developmental stages and lead to 
much more dramatic phenotypes than RP. However, it cannot 
be excluded that other mutations may have milder effects 
and trigger the same photoreceptor cell death pathway as 
for RP-linked splicing factors. The unique novel amino acid 
substitution in the PRPF4 gene (p.Pro187Ala) was difficult 
to interpret in terms of pathogenicity in the absence of addi-
tional genetic or functional elements, but the evidence that 
downregulation of this protein in zebrafish leads to splicing 
defects and photoreceptor degeneration [21] still suggests that 
the gene might have a role in RP, perhaps with low frequency.
In conclusion, we did not find proof that the genes 
EFTUD2, PRPF4, NHP2L1 and AAR2 are associated with 
adRP in patients of European and North American origin. 
However, we cannot exclude that very rare pathogenic muta-
tions exist in these genes in the same ethnic groups or in other 
populations, in virtue of the high genetic heterogeneity of the 
disease, the increasingly low frequency of mutations detected 
in novel RP genes, and of geographical effects.
Note added in proof: While the current article was under 
review, mutations in PRPF4 were identified as a cause of 
dominant RP in a Chinese cohort of patients, highlighting in 
fact a possible population-specific effect [42].
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APPENDIX 1. PRIMERS USED FOR LONG-
RANGE PCR.
To access the data, click or select the words “Appendix 1.”
APPENDIX 2. PRIMERS USED FOR SHORT 
RANGE PCR AND SEQUENCING
To access the data, click or select the words “Appendix 2.”
APPENDIX 3. SUMMARY OF METRICS OF 
NGS SCREENING RUNS AND PER SAMPLE 
STATISTICS.
To access the data, click or select the words “Appendix 3.”
APPENDIX 4. RESULTS OF SPLICE SITES 
ANALYSIS USING THE SHANNON HUMAN 
SPLICING PIPELINE.
To access the data, click or select the words “Appendix 4.”
APPENDIX 5. TOTAL NUMBER OF VARIANTS 
IDENTIFIED BY TWO ALIGNMENTS WITH 
DIFFERENT MAPPING CRITERIA.
To access the data, click or select the words “Appendix 5.”
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